Download PDF
Semin Respir Crit Care Med 2010; 31(3): 267-275
DOI: 10.1055/s-0030-1254067
© Thieme Medical Publishers

The Potential Value of Biomarkers in Diagnosis and Staging of COPD and Exacerbations

Anant R.C Patel1 , John R. Hurst1 , Jadwiga A. Wedzicha1
  • 1Academic Unit of Respiratory Medicine, University College London Medical School, London, United Kingdom
Further Information

Publication History

Publication Date:
21 May 2010 (online)

    Permissions and Reprints

ABSTRACT

There is an unmet need in the diagnosis, phenotyping, and staging of COPD that could potentially be fulfilled by a validated molecular biomarker. Many promising candidates have been investigated, and some have been shown to be useful in certain situations. However, to date there is no outstanding disease-specific biomarker for widespread clinical application for patients in the stable state. Given the functional, social, and financial importance of exacerbations of COPD, it would be very useful to be able to employ a biomarker to aid optimal treatment and predict clinical outcome from the acute episode. Although serum C-reactive protein (CRP) is not specific to COPD, its use as a molecular biomarker in the stable state and at exacerbation has been studied extensively, and it remains the most commonly measured molecular biomarker in routine secondary care practice. Utilizing biomarkers in combinations may ultimately prove more useful. Airway-derived biomarkers and their relationships with outcome measures require further longitudinal study as well as refinement of sampling techniques to make them more broadly applicable. There is substantial ongoing investigation of many biomarkers that we are hopeful will advance the field for the benefit of our patients.

KEYWORDS

COPD - biomarker - phenotype - exacerbation

REFERENCES

  • 1 Atkinson A J, Colburn W A, DeGruttola V G Biomarkers Definitions Working Group et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.  Clin Pharmacol Ther. 2001;  69 89-95
    CrossrefPubMedGoogle Scholar
  • 2 Global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease. Available at http://www.goldcopd.org Accessed November 10, 2009
    Google Scholar
  • 3 Celli B R, Cote C G, Marin J M et al.. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.  N Engl J Med. 2004;  350 1005-1012
    CrossrefPubMedGoogle Scholar
  • 4 Miller M R, Crapo R, Hankinson J ATS/ERS Task Force et al. General considerations for lung function testing.  Eur Respir J. 2005;  26 153-161
    CrossrefPubMedGoogle Scholar
  • 5 Swanney M P, Ruppel G, Enright P L et al.. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction.  Thorax. 2008;  63 1046-1051
    CrossrefPubMedGoogle Scholar
  • 6 Vollmer W M, Gíslason T, Burney P et al.. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study.  Eur Respir J. 2009;  34 588-597
    CrossrefPubMedGoogle Scholar
  • 7 Jones P W, Wijskstra P J. Quality of life in patients with chronic obstructive pulmonary disease. In: Siafakas NM Management of Chronic Obstructive Pulmonary Disease. European Respiratory Monograph 38, Vol 11. Sheffield, UK; European Respiratory Society Journals Ltd 2006: 375-386
    PubMedGoogle Scholar
  • 8 Cazzola M, MacNee W, Martinez F J American Thoracic Society et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers.  Eur Respir J. 2008;  31 416-469
    CrossrefPubMedGoogle Scholar
  • 9 Mortensen R F. C-reactive protein, inflammation, and innate immunity.  Immunol Res. 2001;  24 163-176
    CrossrefPubMedGoogle Scholar
  • 10 Pepys M B, Hirschfield G M. C-reactive protein: a critical update.  J Clin Invest. 2003;  111 1805-1812
    CrossrefPubMedGoogle Scholar
  • 11 McGarvey L P, John M, Anderson J A, Zvarich M, Wise R A. TORCH Clinical Endpoint Committee . Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee.  Thorax. 2007;  62 411-415
    CrossrefPubMedGoogle Scholar
  • 12 Mannino D M, Ford E S, Redd S C. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination.  Am J Med. 2003;  114 758-762
    CrossrefPubMedGoogle Scholar
  • 13 Sin D D, Man S FP. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease.  Circulation. 2003;  107 1514-1519
    CrossrefPubMedGoogle Scholar
  • 14 Pinto-Plata V M, Müllerova H, Toso J F et al.. C-reactive protein in patients with COPD, control smokers and non-smokers.  Thorax. 2006;  61 23-28
    CrossrefPubMedGoogle Scholar
  • 15 Sin D D, Lacy P, York E, Man S F. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2004;  170 760-765
    CrossrefPubMedGoogle Scholar
  • 16 Dahl M, Vestbo J, Lange P, Bojesen S E, Tybjaerg-Hansen A, Nordestgaard B G. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2007;  175 250-255
    CrossrefPubMedGoogle Scholar
  • 17 Man SFP, Connett J E, Anthonisen N R, Wise R A, Tashkin D P, Sin D D. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease.  Thorax. 2006;  61 849-853
    CrossrefPubMedGoogle Scholar
  • 18 de Torres J P, Pinto-Plata V, Casanova C et al.. C-reactive protein levels and survival in patients with moderate to very severe COPD.  Chest. 2008;  133 1336-1343
    PubMedGoogle Scholar
  • 19 de Torres J P, Cordoba-Lanus E, López-Aguilar C et al.. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients.  Eur Respir J. 2006;  27 902-907
    PubMedGoogle Scholar
  • 20 Limper A H, Roman J. Fibronectin: a versatile matrix protein with roles in thoracic development, repair and infection.  Chest. 1992;  101 1663-1673
    CrossrefPubMedGoogle Scholar
  • 21 Man S F, Xing L, Connett J E et al.. Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD?.  Eur Respir J. 2008;  32 1451-1457
    CrossrefPubMedGoogle Scholar
  • 22 Lomas D A, Silverman E K, Edwards L D, Miller B E, Coxson H O, Tal-Singer R. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators . Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort.  Thorax. 2008;  63 1058-1063
    CrossrefPubMedGoogle Scholar
  • 23 Lomas D A, Silverman E K, Edwards L D Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study investigators et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD.  Eur Respir J. 2009;  34 95-102
    CrossrefPubMedGoogle Scholar
  • 24 Bhowmik A, Seemungal T A, Sapsford R J, Devalia J L, Wedzicha J A. Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease.  Thorax. 1998;  53 953-956
    CrossrefPubMedGoogle Scholar
  • 25 Keatings V M, Collins P D, Scott D M, Barnes P J. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma.  Am J Respir Crit Care Med. 1996;  153 530-534
    PubMedGoogle Scholar
  • 26 Yamamoto C, Yoneda T, Yoshikawa M et al.. Airway inflammation in COPD assessed by sputum levels of interleukin-8.  Chest. 1997;  112 505-510
    CrossrefPubMedGoogle Scholar
  • 27 Kostikas K, Papatheodorou G, Psathakis K, Panagou P, Loukides S. Oxidative stress in expired breath condensate of patients with COPD.  Chest. 2003;  124 1373-1380
    CrossrefPubMedGoogle Scholar
  • 28 Montuschi P, Collins J V, Ciabattoni G et al.. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers.  Am J Respir Crit Care Med. 2000;  162(3 Pt 1) 1175-1177
    CrossrefPubMedGoogle Scholar
  • 29 Horváth I, Hunt J, Barnes P J ATS/ERS Task Force on Exhaled Breath Condensate et al. Exhaled breath condensate: methodological recommendations and unresolved questions.  Eur Respir J. 2005;  26 523-548
    CrossrefPubMedGoogle Scholar
  • 30 Rutgers S R, van der Mark T W, Coers W et al.. Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease.  Thorax. 1999;  54 576-580
    CrossrefPubMedGoogle Scholar
  • 31 Bhowmik A, Seemungal T A, Donaldson G C, Wedzicha J A. Effects of exacerbations and seasonality on exhaled nitric oxide in COPD.  Eur Respir J. 2005;  26 1009-1015
    CrossrefPubMedGoogle Scholar
  • 32 Brindicci C, Ito K, Resta O, Pride N B, Barnes P J, Kharitonov S A. Exhaled nitric oxide from lung periphery is increased in COPD.  Eur Respir J. 2005;  26 52-59
    CrossrefPubMedGoogle Scholar
  • 33 Fens N, Zwinderman A H, van der Schee M P et al.. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma.  Am J Respir Crit Care Med. 2009;  180 1076-1082
    CrossrefPubMedGoogle Scholar
  • 34 Donaldson G C, Seemungal T A, Bhowmik A, Wedzicha J A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.  Thorax. 2002;  57 847-852
    CrossrefPubMedGoogle Scholar
  • 35 Seemungal T A, Donaldson G C, Paul E A, Bestall J C, Jeffries D J, Wedzicha J A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1998;  157(5 Pt 1) 1418-1422
    CrossrefPubMedGoogle Scholar
  • 36 Garcia-Aymerich J, Farrero E, Félez M A, Izquierdo J, Marrades R M, Antó J M. Estudi del Factors de Risc d'Agudització de la MPOC investigators . Risk factors of readmission to hospital for a COPD exacerbation: a prospective study.  Thorax. 2003;  58 100-105
    CrossrefPubMedGoogle Scholar
  • 37 Soler-Cataluña J J, Martínez-García M A, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.  Thorax. 2005;  60 925-931
    CrossrefPubMedGoogle Scholar
  • 38 Wedzicha J A, Seemungal T A. COPD exacerbations: defining their cause and prevention.  Lancet. 2007;  370 786-796
    CrossrefPubMedGoogle Scholar
  • 39 Hurst J R, Perera W R, Wilkinson T M, Donaldson G C, Wedzicha J A. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2006;  173 71-78
    CrossrefPubMedGoogle Scholar
  • 40 Hurst J R, Donaldson G C, Perera W R et al.. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2006;  174 867-874
    CrossrefPubMedGoogle Scholar
  • 41 Bozinovski S, Hutchinson A, Thompson M et al.. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2008;  177 269-278
    PubMedGoogle Scholar
  • 42 Stolz D, Christ-Crain M, Morgenthaler N G et al.. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD.  Chest. 2007;  131 1058-1067
    CrossrefPubMedGoogle Scholar
  • 43 Perera W R, Hurst J R, Wilkinson T M et al.. Inflammatory changes, recovery and recurrence at COPD exacerbation.  Eur Respir J. 2007;  29 527-534
    CrossrefPubMedGoogle Scholar
  • 44 Seemungal T A, Donaldson G C, Bhowmik A, Jeffries D J, Wedzicha J A. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2000;  161 1608-1613
    CrossrefPubMedGoogle Scholar
  • 45 Rohde G, Wiethege A, Borg I et al.. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study.  Thorax. 2003;  58 37-42
    CrossrefPubMedGoogle Scholar
  • 46 Spurrell J C, Wiehler S, Zaheer R S, Sanders S P, Proud D. Human airway epithelial cells produce IP-10 (CXCL10) in vitro and in vivo upon rhinovirus infection.  Am J Physiol Lung Cell Mol Physiol. 2005;  289 L85-L95
    CrossrefPubMedGoogle Scholar
  • 47 Quint J K, Donaldson G C, Goldring J J, Baghai-Ravary R, Hurst J R, Wedzicha J A. Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD.  Chest. 2009;  , October 16 [Epub ahead of print]
    PubMedGoogle Scholar
  • 48 Bhowmik A, Seemungal T A, Sapsford R J, Wedzicha J A. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations.  Thorax. 2000;  55 114-120
    CrossrefPubMedGoogle Scholar
  • 49 Patel I S, Seemungal T A, Wilks M, Lloyd-Owen S J, Donaldson G C, Wedzicha J A. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations.  Thorax. 2002;  57 759-764
    CrossrefPubMedGoogle Scholar
  • 50 Donaldson G C, Seemungal T A, Patel I S et al.. Airway and systemic inflammation and decline in lung function in patients with COPD.  Chest. 2005;  128 1995-2004
    CrossrefPubMedGoogle Scholar
  • 51 Zhang W, Yan S D, Zhu A et al.. Expression of Egr-1 in late stage emphysema.  Am J Pathol. 2000;  157 1311-1320
    CrossrefPubMedGoogle Scholar
  • 52 Ning W, Li C J, Kaminski N et al.. Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease.  Proc Natl Acad Sci U S A. 2004;  101 14895-14900
    CrossrefPubMedGoogle Scholar
  • 53 Ning W, Lee J, Kaminski N et al.. Comprehensive analysis of gene expression on GOLD-2 Versus GOLD-0 smokers reveals novel genes important in the pathogenesis of COPD.  Proc Am Thorac Soc. 2006;  3 466
    CrossrefPubMedGoogle Scholar
  • 54 Bhattacharya S, Srisuma S, Demeo D L et al.. Molecular biomarkers for quantitative and discrete COPD phenotypes.  Am J Respir Cell Mol Biol. 2009;  40 359-367
    CrossrefPubMedGoogle Scholar

Anant R.C PatelM.B. B.S. 

Academic Unit of Respiratory Medicine, University College London Medical School

Royal Free Campus, Rowland Hill St., London NW3 2PF, UK

Email: anant.patel@medsch.ucl.ac.uk

      >